POC Hemostasis System Could Help Prevent Maternal Deaths
Posted on 27 Dec 2024
Postpartum hemorrhage (PPH), which refers to severe bleeding following childbirth, is the leading cause of maternal deaths globally. Every year, about 14 million women experience PPH, and approximately 70,000 die as a result. This issue is not limited to developing countries, as the United States reports 21.1 deaths per 100,000 live births, nearly double the average in countries belonging to the Organization for Economic Cooperation and Development (OECD), with over 10% of maternal deaths attributed to excessive bleeding. Now, new research is exploring how a novel hemostasis system could potentially improve the management of peripartum bleeding in obstetric patients.
HemoSonics (Durham, NC, USA) is researching the role of its Quantra Hemostasis System in enhancing the management of peripartum bleeding. The system includes the Quantra Hemostasis Analyzer, equipped with QPlus and QStat Cartridges, which provide clinicians with valuable data to guide patient-centered decisions regarding bleeding control, improving care and optimizing blood product use. The Quantra System utilizes SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary ultrasound technology that assesses the coagulation properties of whole blood samples.
This system is easy to maintain, simple to operate and interpret, and offers rapid, comprehensive whole-blood coagulation analysis in under 15 minutes, whether at the point of care or in laboratory settings. The Quantra System is FDA-cleared for use in cardiovascular surgeries, trauma, liver transplants, and major orthopedic procedures. It helps hospitals standardize their viscoelastic testing processes in a clinically efficient and operationally effective manner. Recently, HemoSonics was selected as one of the final winners for the RADx Tech for Maternal Health Challenge from over 80 submissions for efforts to improve postpartum maternal health and health equity with innovative diagnostic tools.
“It is a tremendous validation to receive the RADx award and recognition from NIH to help support research for how the Quantra Hemostasis System may help obstetric patients,” said HemoSonics’ President and CEO Bob Roda. “Along with the other winners, HemoSonics will work tirelessly to advance technologies that help women have safe and healthy deliveries, wherever they may live, and to improve overall maternal health.”
Related Links:
HemoSonics
